These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23722471)

  • 1. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.
    Cybulski C; Wokołorczyk D; Kluźniak W; Kashyap A; Gołąb A; Słojewski M; Sikorski A; Puszyński M; Soczawa M; Borkowski T; Borkowski A; Antczak A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Domagała P; Piotrowski K; Menkiszak J; Krzystolik K; Gronwald J; Jakubowska A; Górski B; Dębniak T; Masojć B; Huzarski T; Muir KR; Lophatananon A; Lubiński J; Narod SA;
    Br J Cancer; 2013 Jun; 108(12):2601-9. PubMed ID: 23722471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An inherited NBN mutation is associated with poor prognosis prostate cancer.
    Cybulski C; Wokołorczyk D; Kluźniak W; Jakubowska A; Górski B; Gronwald J; Huzarski T; Kashyap A; Byrski T; Dębniak T; Gołąb A; Gliniewicz B; Sikorski A; Switała J; Borkowski T; Borkowski A; Antczak A; Wojnar L; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Narod SA; Lubiński J;
    Br J Cancer; 2013 Feb; 108(2):461-8. PubMed ID: 23149842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
    Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
    Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome.
    Lener MR; Kashyap A; Kluźniak W; Cybulski C; Soluch A; Pietrzak S; Huzarski T; Gronwald J; Lubiński J
    Cancer Res Treat; 2017 Apr; 49(2):430-436. PubMed ID: 27488870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?
    Lener MR; Scott RJ; Kluźniak W; Baszuk P; Cybulski C; Wiechowska-Kozłowska A; Huzarski T; Byrski T; Kładny J; Pietrzak S; Soluch A; Jakubowska A; Lubiński J
    Int J Cancer; 2016 Aug; 139(3):601-6. PubMed ID: 27038244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The presence of prostate cancer at biopsy is predicted by a number of genetic variants.
    Kashyap A; Kluźniak W; Wokołorczyk D; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Świtała J; Borkowski T; Borkowski A; Antczak A; Wojnar Ł; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Piotrowski K; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Górski B; Masojć B; van de Wetering T; Menkiszak J; Akbari MR; Lubiński J; Narod SA; Cybulski C;
    Int J Cancer; 2014 Mar; 134(5):1139-46. PubMed ID: 24037955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
    Górski B
    Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
    Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
    Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
    Sessine MS; Das S; Park B; Salami SS; Kaffenberger SD; Kasputis A; Solorzano M; Luke M; Vince RA; Kaye DR; Borza T; Stoffel EM; Cobain E; Merajver SD; Jacobs MF; Milliron KJ; Caba L; van Neste L; Mondul AM; Morgan TM
    Urology; 2021 Oct; 156():96-103. PubMed ID: 34280438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.
    Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Zdrojowy R; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Narod SA; Lubiński J
    J Med Genet; 2006 Nov; 43(11):863-6. PubMed ID: 17085682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations.
    Kaufman B; Laitman Y; Gronwald J; Winqvist R; Irmejs A; Lubinski J; Pylkäs K; Gardovskis J; Miklasevics E; Friedman E
    Fam Cancer; 2009; 8(4):473-8. PubMed ID: 19609724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of Gene Mutations and Polymorphic Variants and their Association with Prostate Cancer Risk in Polish Men.
    Heise M; Jarzemski P; Nowak D; Bąk A; Junkiert-Czarnecka A; Pilarska-Deltow M; Borysiak M; Pilarska B; Haus O
    Cancer Control; 2022; 29():10732748211062342. PubMed ID: 35638715
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
    Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA;
    Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.
    Sokolenko AP; Rozanov ME; Mitiushkina NV; Sherina NY; Iyevleva AG; Chekmariova EV; Buslov KG; Shilov ES; Togo AV; Bit-Sava EM; Voskresenskiy DA; Chagunava OL; Devilee P; Cornelisse C; Semiglazov VF; Imyanitov EN
    Fam Cancer; 2007; 6(3):281-6. PubMed ID: 17333477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.
    Novak DJ; Chen LQ; Ghadirian P; Hamel N; Zhang P; Rossiny V; Cardinal G; Robidoux A; Tonin PN; Rousseau F; Narod SA; Foulkes WD
    BMC Cancer; 2008 Aug; 8():239. PubMed ID: 18706089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of incorporating genetic variants for the early detection of prostate cancer.
    Nam RK; Zhang WW; Trachtenberg J; Seth A; Klotz LH; Stanimirovic A; Punnen S; Venkateswaran V; Toi A; Loblaw DA; Sugar L; Siminovitch KA; Narod SA
    Clin Cancer Res; 2009 Mar; 15(5):1787-93. PubMed ID: 19223501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The digital rectal examination (DRE) remains important - outcomes from a contemporary cohort of men undergoing an initial 12-18 core prostate needle biopsy.
    Palmerola R; Smith P; Elliot V; Reese CT; Mahon FB; Harpster LE; Icitovic N; Raman JD
    Can J Urol; 2012 Dec; 19(6):6542-7. PubMed ID: 23228289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.
    Liss MA; Xu J; Chen H; Kader AK
    Prostate; 2015 Sep; 75(12):1322-8. PubMed ID: 25982801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.